Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson’s Disease

被引：0
作者：
Manuela Contin
Roberto Riva
Fiorenzo Albani
Agostino Baruzzi
机构：
[1] University of Bologna,Laboratory of Clinical Neuropharmacology, Institute of Neurology
来源：
CNS Drugs | 2000年 / 14卷
关键词：
Levodopa; Bromocriptine; Dopamine Agonist; Apomorphine; Pramipexole;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dopamine receptor agonists were originally developed as adjunctive therapies to ‘smooth out’ motor response fluctuations to levodopa in patients with advanced Parkinson’s disease. However, they are now used in the early stages of the disease, in monotherapy or combination with low doses of levodopa, to delay the onset of levodopa therapy and its complications.
引用
收藏
页码：439 / 455
页数：16
相关论文
共 387 条
[1]  
Kish SJ(1988)Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease: pathophysiologic and clinical implications N Engl J Med 318 876-81
[2]  
Shannak K(1994)Parkinson’s disease J Neurol Neurosurg Psychiatry 57 672-81
[3]  
Homykiewic O(1987)On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics Ann Neurol 22 535-40
[4]  
Marsden CD(1988)Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, part II Ann Neurol 24 372-8
[5]  
Nutt JG(1988)Pathogenesis of dyskinesias in Parkinson’s disease Ann Neurol 25 523-6
[6]  
Mouradian MM(1994)L-3-4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors J Neurochem 63 108-17
[7]  
Juncos JL(1994)A hypothesis on the pathophysiologic mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson’s disease: implications for future strategies in treatment Movement Disord 5 100-8
[8]  
Fabbrini G(1986)Episodic unresponsiveness to single doses of 1-dopa in parkinsonian fluctuators Neurology 36 100-3
[9]  
Mouradian MM(1996)Treatment of early Parkinson’s disease: are complicated strategies justified? Mayo Clin Proc 71 659-70
[10]  
Heuser IJ(1999)Dopamine agonists: what is the place of the newe r compounds in the treatment of Parkinson’s disease? J Neural Transm [P-D Sect] 55 33-45
12345678910